Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Aug 12

PMID 35956752

Authors

Haobin Zhao

Di Wang

Zhifu Zhang

Junfang Xian

Xiaosu Bai

Affiliations

Soon will be listed here.

Abstract

The human gut is inhabited by hundreds of billions of commensal microbiota that collectively produce thousands of small molecules and metabolites with local and systemic effects on the physiology of the host. Much evidence from preclinical to clinical studies has gradually confirmed that the gut microbiota can regulate anti-tumor immunity and affect the efficacy of cancer immune checkpoint inhibitors (ICIs) therapy. In particular, one of the main modes of gut microbiota regulating anti-tumor immunity is through metabolites, which are small molecules that can be transported in the body and act on local and systemic anti-tumor immune responses to promote ICIs immunotherapy efficacy. We discuss the functions of microbial metabolites in humans, focusing on the effects and mechanisms of microbial metabolites on immunotherapy, and analyze their potential applications as immune adjuvants and therapeutic targets to regulate immunity and enhance ICIs. In summary, this review provides the basis for the rational design of microbiota and microbial metabolite-based strategies of enhancing ICIs.

Citing Articles

Gut Microbiota Secondary Metabolites: Key Roles in GI Tract Cancers and Infectious Diseases.

Anwer E, Ajagbe M, Sherif M, Musaibah A, Mahmoud S, ElBanbi A Biomedicines. 2025; 13(1).

PMID: 39857684 PMC: 11762448. DOI: 10.3390/biomedicines13010100.

Contribution of tryptophan and its metabolites to transplant outcome: a mini-review.

Donoso-Meneses D, Padilla C, Moya-Guzman M, Alegre M, Pino-Lagos K Front Immunol. 2024; 15:1395421.

PMID: 39474416 PMC: 11518742. DOI: 10.3389/fimmu.2024.1395421.

Harmony unveiled: Intricate the interplay of dietary factor, gut microbiota, and colorectal cancer-A narrative review.

Endale H, Tesfaye W, Hassen F, Asrat W, Temesgen E, Yimer Shibabaw Y SAGE Open Med. 2024; 12:20503121241274724.

PMID: 39224896 PMC: 11367611. DOI: 10.1177/20503121241274724.

Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review).

Zhou Y, Han W, Feng Y, Wang Y, Sun T, Xu J Int J Oncol. 2024; 65(1).

PMID: 38847233 PMC: 11173369. DOI: 10.3892/ijo.2024.5661.

Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial.

Kragsnaes M, Jensen J, Nilsson A, Malik M, Munk H, Pedersen J RMD Open. 2024; 10(1).

PMID: 38296309 PMC: 10836383. DOI: 10.1136/rmdopen-2023-003750.

References

Chun E, Lavoie S, Fonseca-Pereira D, Bae S, Michaud M, Hoveyda H . Metabolite-Sensing Receptor Ffar2 Regulates Colonic Group 3 Innate Lymphoid Cells and Gut Immunity. Immunity. 2019; 51(5):871-884.e6. PMC: 6901086. DOI: 10.1016/j.immuni.2019.09.014. View

Coutzac C, Jouniaux J, Paci A, Schmidt J, Mallardo D, Seck A . Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun. 2020; 11(1):2168. PMC: 7195489. DOI: 10.1038/s41467-020-16079-x. View

Cummings J, Pomare E, Branch W, Naylor C, Macfarlane G . Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987; 28(10):1221-7. PMC: 1433442. DOI: 10.1136/gut.28.10.1221. View

Lees H, Swann J, Wilson I, Nicholson J, Holmes E . Hippurate: the natural history of a mammalian-microbial cometabolite. J Proteome Res. 2013; 12(4):1527-46. DOI: 10.1021/pr300900b. View

Yang W, Yu T, Huang X, Bilotta A, Xu L, Lu Y . Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun. 2020; 11(1):4457. PMC: 7478978. DOI: 10.1038/s41467-020-18262-6. View

Allen A, Flemstrom G . Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol. 2004; 288(1):C1-19. DOI: 10.1152/ajpcell.00102.2004. View

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M . Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018; 360(6391). PMC: 6407885. DOI: 10.1126/science.aan5931. View

Roager H, Licht T . Microbial tryptophan catabolites in health and disease. Nat Commun. 2018; 9(1):3294. PMC: 6098093. DOI: 10.1038/s41467-018-05470-4. View

Dupraz L, Magniez A, Rolhion N, Richard M, Da Costa G, Touch S . Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal γδ T cells. Cell Rep. 2021; 36(1):109332. DOI: 10.1016/j.celrep.2021.109332. View

10.

Kelly C, Zheng L, Campbell E, Saeedi B, Scholz C, Bayless A . Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe. 2015; 17(5):662-71. PMC: 4433427. DOI: 10.1016/j.chom.2015.03.005. View

11.

Lim S, Wei J, Nguyen T, Shi H, Su W, Palacios G . Lipid signalling enforces functional specialization of T cells in tumours. Nature. 2021; 591(7849):306-311. PMC: 8168716. DOI: 10.1038/s41586-021-03235-6. View

12.

Nomura M, Nagatomo R, Doi K, Shimizu J, Baba K, Saito T . Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors. JAMA Netw Open. 2020; 3(4):e202895. PMC: 7163404. DOI: 10.1001/jamanetworkopen.2020.2895. View

13.

Kim C . Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids. Cell Mol Immunol. 2021; 18(5):1161-1171. PMC: 8093302. DOI: 10.1038/s41423-020-00625-0. View

14.

Myers J, Miller J . Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2020; 18(2):85-100. PMC: 8316981. DOI: 10.1038/s41571-020-0426-7. View

15.

Song X, An Y, Chen D, Zhang W, Wu X, Li C . Microbial metabolite deoxycholic acid promotes vasculogenic mimicry formation in intestinal carcinogenesis. Cancer Sci. 2021; 113(2):459-477. PMC: 8819290. DOI: 10.1111/cas.15208. View

16.

Cho C, Taesuwan S, Malysheva O, Bender E, Tulchinsky N, Yan J . Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: A randomized controlled trial. Mol Nutr Food Res. 2016; 61(1). DOI: 10.1002/mnfr.201600324. View

17.

Hersi F, Elgendy S, Al Shamma S, Altell R, Sadiek O, Omar H . Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites. Life Sci. 2022; 300:120573. DOI: 10.1016/j.lfs.2022.120573. View

18.

Guo Y, Liu Y, Wu W, Ling D, Zhang Q, Zhao P . Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy. Biomaterials. 2021; 276:121018. DOI: 10.1016/j.biomaterials.2021.121018. View

19.

Sugimura N, Li Q, Chu E, Lau H, Fong W, Liu W . modulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis. Gut. 2021; . PMC: 9484392. DOI: 10.1136/gutjnl-2020-323951. View

20.

Luu M, Riester Z, Baldrich A, Reichardt N, Yuille S, Busetti A . Microbial short-chain fatty acids modulate CD8 T cell responses and improve adoptive immunotherapy for cancer. Nat Commun. 2021; 12(1):4077. PMC: 8249424. DOI: 10.1038/s41467-021-24331-1. View